ClinicalTrials.gg
Sign In
Not yet recruitingNCT06735703Updated Dec 16, 2024

Group B Streptococcus Infection and PROM Incidince

An observational study in Premature Rupture of Fetal Membranes and Group B Streptococcal Infection, sponsored by Assiut University. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by Assiut University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Sex
Female
01

Study summary

To investigate incidince of prom with GBS infection and role of prophylaxis against it

02

Conditions studied

  • Premature Rupture of Fetal Membranes
  • Group B Streptococcal Infection
03

In context

Fetal Membranes, Premature Rupture

100 studies on the registry are indexed under Fetal Membranes, Premature Rupture; 23 are open to participants now.

This study's planned enrollment of 150 is above the median of 122 across 36 observational studies indexed under Fetal Membranes, Premature Rupture.

Browse Fetal Membranes, Premature Rupture studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse Assiut University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pregnant women with prom

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women with prom after 34 wks festation

Exclusion criteria

Exclusion Criteria:

  • Bleeding disorder
  • emergency conditions
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pregnant women after 34 wks with PROM

    Drug: To provide ampicillin sulbactam to pregnant women with premature rupture of membrane

Interventions

  • DrugTo provide ampicillin sulbactam to pregnant women with premature rupture of membrane

    To provide ampicillin sulbactam tonpregnant women with premature rupture of membrane after 34 wks gestation

06

What researchers measure

Primary outcomes

  1. Incidince of prom with GBS infection and prophylaxis against it

    Time frame: Baseline

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2024; primary completion for Dec 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 16, 2024
StartEst.
Dec 25, 2024
Primary completionEst.
Dec 9, 2025
CompletionEst.
Jan 9, 2026
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06735703
Lead sponsor
Assiut University
Responsible party
Dina Mohamed Kamel (Dina mohamedkamel, Assiut University) — Principal investigator
First posted
Dec 16, 2024
Start date
Dec 25, 2024 (estimated)
Primary completion
Dec 9, 2025 (estimated)
Completion
Jan 9, 2026 (estimated)
Last update
Dec 16, 2024

Study contacts

Dina Mohamed Kamel
Contact
dinakamel802@gmail.com
0927923623
Sherif Abdelmeged badran
Contact
0927923623

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Fetal Membranes, Premature Rupture →

Other studies from this sponsor

Assiut University →

Start the discussion